How AI Will Accelerate Breakthroughs in Biotechnology with Benchling CEO Sajith Wickramasekara
Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the central system of record for biotech R&D, but…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from No Priors: Artificial Intelligence | Technology | Startups
See all episodes →
43%From Restoring Sight to Reimagining the Brain, with Max Hodak
35%Redefining Chip Architecture with Arm CEO Rene Haas
33%Rethinking Legacy Data Infrastructure with Eon Co-Founders Ofir Ehrlich and Gonen Stein
Similar episodes from other shows
More like No Priors: Artificial Intelligence | Technology | Startups →
Can America Win The AI Biotech Race Against China? | Lada Nuzhna & Elliot Hershberg
EP 27: AI Revolutionizing Drug Discovery (2023 - 2025)
EP 32: AI Discovers Drugs: The 2026 Clinical Trial Moment for AI in Biotech
🔬Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.